Leu-Enkephalin (trifluoroacetate salt)
(Synonyms: Leucine enkephalin, Leu5enkephalin, Tyr-Gly-Gly-Phe-Leu-OH) 目录号 : GC49720A neuropeptide and δ- and ?-opioid receptor agonist
Cas No.:73563-78-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Leu-Enkephalin is an endogenous neuropeptide involved in nociception and an agonist of δ- and µ-opioid receptors (Kis = 4.0 and 3.4 nM, respectively).1,2 It is selective for δ- and µ- over κ-opioid receptors (Ki = >1,000 nM).2 Leu-Enkephalin is a cleavage product of proenkephalin, which is found primarily in the adrenal medulla and the CNS.3 It is found in the brain, the brainstem, and the spinal cord as well as in the peripheral nervous system. Leu-Enkephalin (1 mg/kg) decreases the visceromotor response to colon distension in a mouse model of visceral pain induced by colorectal distension.4 It also increases the tail-flick threshold and latency to tail flick in the tail-pressure test and tail-flick test, respectively, in mice.5
1.Hughes, J., Smith, T.W., Kosterlitz, H.W., et al.Identification of two related pentapeptides from the brain with potent opiate agonist activityNature258(5536)577-580(1975) 2.Raynor, K., Kong, H., Chen, Y., et al.Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptorsMol. Pharm.45(2)330-334(1994) 3.Roques, B.P., Noble, F., and FourniÉ-Zaluski, M.-C.Endrogenous opioid peptides and analgesiaOpioids in pain control: Basic and clinical aspects22-25(1999) 4.Fabisiak, A., Sobociska, M., Kamysz, E., et al.Antinociceptive potency of enkephalins and enkephalinase inhibitors in the mouse model of colorectal distension-proof-of-conceptChem. Biol. Drug Des.92(1)1387-1392(2018) 5.Honda, M., Okutsu, H., Matsuura, T., et al.Spinorphin, an endogenous inhibitor of enkephalin-degrading enzymes, potentiates leu-enkephalin-induced anti-allodynic and antinociceptive effects in miceJpn. J. Pharmacol.87(4)261-267(2001)
Cas No. | 73563-78-7 | SDF | Download SDF |
别名 | Leucine enkephalin, Leu5enkephalin, Tyr-Gly-Gly-Phe-Leu-OH | ||
Canonical SMILES | OC(C(F)(F)F)=O.CC(C)C[C@@H](C(O)=O)NC([C@@H](NC(CNC(CNC([C@@H](N)CC1=CC=C(C=C1)O)=O)=O)=O)CC2=CC=CC=C2)=O | ||
分子式 | C28H37N5O7 • CF3COOH | 分子量 | 669.7 |
溶解度 | DMF: 25 mg/ml,DMSO: 25 mg/ml,Ethanol: 25 mg/ml,PBS (pH 7.2): 10 mg/ml | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.4932 mL | 7.466 mL | 14.9321 mL |
5 mM | 0.2986 mL | 1.4932 mL | 2.9864 mL |
10 mM | 0.1493 mL | 0.7466 mL | 1.4932 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Peptide characterization with a sulfoethyl aspartamide column
J Chromatogr 1988 Jun 29;443:63-71.PMID:2844842DOI:10.1016/s0021-9673(00)94783-6.
A strong cation-exchange (SCX) high-performance liquid chromatography column (sulfoethyl aspartamide, 200 x 4.6 mm) was used to analyze more than 50 peptides, ranging in length from 5 to 20 residues. These data show that the elution positions of the peptides increase monotonically with the number of positively charged residues. [A 60-min linear gradient of 0 to 100% eluent B at 1 ml/min was used, where eluent A is 5 mM phosphate (pH 3.0)-acetonitrile (75:25) and eluent B is eluent A + 0.5 M sodium chloride.] A comparison of SCX with a standard C18 reversed-phase (RP) column [60-min linear gradient of 0 to 60% B at 1 ml/min, where eluent A is 0.1% trifluoroacetic acid (TFA), and eluent B is 0.095% TFA-acetonitrile (10:90)] further demonstrates the utility of SCX in peptide characterization. SCX separated an (Arg)3-containing peptide from the Arg-deleted peptide while RP could not. In addition, SCX and RP resolved the methionine oxidation products of ACTH (4-10) (RP: Met [O] less than Met [O2] less than Met; SCX; Met [O] less than Met less than Met [O2]), suggesting a mixed-mode mechanism for the ion-exchange system. Finally, SCX separated the sulfated and non-sulfated forms of cholecystokinin (26-33) and Leu-Enkephalin as well as the N-terminal acetylated forms of neurotensin (8-13) and angiotensinogen (1-14) from the respective unmodified peptides.